To the Editor We read with great interest the work by Theelen et al,1 which reported that treatment with pembrolizumab combined with radiotherapy had a manageable safety profile and synergistic effect. We think that the work provides powerful clinical data to this field. Although the authors suggested that radiotherapy prior to treatment with pembrolizumab was well tolerated and conferred notably improved outcomes, we would like to raise 3 points for discussion.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zhang B, Han B. Going Beyond Results of the PEMBRO-RT Trial. JAMA Oncol. Published online November 21, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.5031
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: